Follow us on Twitter
twitter icon@FreshPatents

G Protein patents

Bulk PDF Downloads
      

This page is updated frequently with new G Protein-related patent applications.




 Method to improve protein production patent thumbnailMethod to improve protein production
Method to create in silico protein mutants with improved expression level in an expression host compared to an original protein. The mutants retain unaltered or minimally altered function and specific activity that is at the same or higher level compared to the original protein.

 Expression system for producing protein having a n-terminal pyroglutamate residue patent thumbnailExpression system for producing protein having a n-terminal pyroglutamate residue
Disclosed herein is an expression system and uses thereof. The expression system comprises two vectors that express two fusion proteins and a glutaminyl cyclase (qc) with e45q mutation, so as to autonomously produce a target protein having a n-terminal pyroglutamate (pglu) residue in a host cell.
Academia Sinica


 Method of using a mir172 molecule for decreasing inflammation patent thumbnailMethod of using a mir172 molecule for decreasing inflammation
An exemplary embodiment relates to a method of using a plant-derived mir172 molecule or its synthetic equivalent, selected from amongst mir172a or mir172b, for decreasing inflammatory processes in an organism, a method of decreasing b and t lymphocyte proliferation, as well as a method of reducing protein fan (factor associated with neutral sphingomyelinase activation) level. Exemplary embodiments provide a novel therapeutic method based on mirna molecules, which through the interaction with mrna encoding fan protein, negatively regulate its expression and decrease the inflammatory response of the organism..
Uniwersytet Im. Adama Mickiewicza W Poznaniu


 Enterobacteriaceae bacteria exhibiting increased l-cysteine producing ability patent thumbnailEnterobacteriaceae bacteria exhibiting increased l-cysteine producing ability
L-cysteine can be produced inexpensively and efficiently by using a bacterium belonging to the family enterobacteriaceae modified to reduce activity of o-acetylserine sulfhydrylase b thereof, the bacterium being modified so that the c terminal region of its thiosulfate-binding protein is deleted, and the bacterium having an increased ability to produce l-cysteine in the presence of a sulfate.. .
National University Corporation Nara Institute Of Science And Technology


 Antibodies and fragments thereof raised against the alpha-3 domain of hla-g protein, methods and means for their preparation, and uses thereof patent thumbnailAntibodies and fragments thereof raised against the alpha-3 domain of hla-g protein, methods and means for their preparation, and uses thereof
An antibody or antigen-binding fragment thereof which specifically binds the α3 domain of a hla-g protein, in particular binds the β2-microglobulin free hla-g protein exhibiting an α3 domain. The nucleic acid molecules encoding a human hla-g α3 domain polypeptide, which is selected from a group of specific sequences, and vectors for the cloning and/or expression of such nucleic acid molecules, recombined cells or cell lines and compositions for use in a host in need thereof to interfere with and neutralize the immune down-regulation due to hla-g proteins, and/or improving or treating conditions showing hla-g+ lesions, and/or improving or treating a neoplasic condition or disease.
Invectys


 Il-13 binding proteins and uses thereof patent thumbnailIl-13 binding proteins and uses thereof
Novel anti-il-13 antigen-binding proteins such as antibodies and antigen-binding fragments thereof are provided. Methods of using the proteins to reduce il-13 activity and to treat il-13-associated diseases and conditions are further provided..
Medimmune Limited


 Tnf-alpha binding proteins patent thumbnailTnf-alpha binding proteins
Tnf-α binding proteins, including chimeric, cdr-grafted, and humanized antibodies that bind tnf-α are provided. Binding proteins have high affinity for tnf-α and neutralize tnf-α activity.
Abbvie Inc.


 Protein separations using an acrylamide containing filter patent thumbnailProtein separations using an acrylamide containing filter
Novel compositions for re-moving impurities such as, protein aggregates, from a sample containing a protein of interest, e.g., an antibody. Such compositions can be used prior to the virus filtration step during protein purification, to remove aggregates and protect the virus filter from fouling, therefore improving virus filter capacity.
Emd Millipore Corporation


 Pharmaceutical compositions patent thumbnailPharmaceutical compositions
A composition including lactoferrin and immunoglobulin, wherein the composition does not substantially include one or more of the following proteins: lactoperoxidase, lactoglobulin, albumin.. .
Probiotec Limited


 Implantable biosensor and methods of use thereof patent thumbnailImplantable biosensor and methods of use thereof
Provided herein is a stabilized oxygen transport matrix that includes a reversible oxygen binding protein, such as hemoglobin, immobilized throughout the stabilized oxygen transport matrix. The stabilized oxygen transport matrix is used to transport oxygen and can be used as an oxygen transport region and a reaction region of an analyte sensor, such as an implantable glucose sensor.
Metronom Health, Inc.


Biological sensing device and separating biomolecule


A biological sensing device and a method for separating a biomolecule are provided. The biological sensing device includes an amino acid sequence and a signal-generating unit.
National Chiao Tung University


Method for analyzing protein-protein interaction on single-molecule level in cell environment, and measuring density of protein activated in cytosol


A method of analyzing protein-protein interactions at a single molecular level is disclosed. The method of analyzing the interactions between first proteins and second proteins at the single molecular level includes: preparing at least two substrates, in which first protein-binding molecules that are biomolecules to be bound to the first proteins are attached to each of the substrates; inducing binding between the first proteins and the first protein-binding molecules on the first substrate and the second substrate, respectively, by supplying the first proteins included in the control group-cell to the first substrate among the two substrates and supplying the first proteins included in the experimental group-cell to the second substrate among the two substrates; supplying cell lysates of cells including the marker-tagged second proteins to the first substrate and the second substrate, respectively, when the first proteins and the first protein-binding molecules are bound to the first substrate and the second substrate, respectively; and comparing and analyzing the interactions between the first proteins and the second proteins on the first substrate and the second substrate in the supply of the cell lysates to the first substrate and the second substrate, respectively.
Korea Advanced Institute Of Science And Technology


Methods for producing a paired tag from a nucleic acid sequence and methods of use thereof


Methods for producing a paired tag from a nucleic acid sequence are provided in which the paired tag comprises the 5′ end tag and 3′ end tag of the nucleic acid sequence. In one embodiment, the nucleic acid sequence comprises two restriction endonuclease recognition sites specific for a restriction endonuclease that cleaves the nucleic acid sequence distally to the restriction endonuclease recognition sites.
Applied Biosystems Llc


Method for synthesizing protein nanoparticles using waste chicken feathers


The embodiments herein disclose a method of synthesizing protein nanoparticles from waste chicken feathers by enzymatic hydrolysis followed by ultrasonic treatment. The steps for the synthesis of the protein nanoparticles include pretreatment of the chicken feathers.

Tslp binding proteins


The present disclosure relates to tslp binding proteins, such as anti-tslp single variable domains, polynucleotides encoding such tslp binding proteins, pharmaceutical compositions and kits comprising said tslp binding proteins and methods of manufacture. The present invention also concerns the use of such tslp binding proteins in the treatment of diseases associated tslp signaling, such as asthma..
Glaxosmithkline Intellectual Property Development Limited


Anti-ngf antibodies and their use


The present disclosure encompasses ngf binding proteins, specifically to antibodies that are chimeric, cdr grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting ngf and for inhibiting ngf activity, e.g., in a mammal subject suffering from a disorder in which ngf activity is detrimental..
Zoetis Belgium S.a.


Therapeutic compounds and methods


Regulator of g protein signaling (rgs) proteins modulate the complex signaling pathways elicited by g protein coupled receptor activation. Recent studies have implicated rgs proteins in the development and progression of multiple cancers.
University Of Iowa Research Foundation


Methods, systems and compositions relating to cell conversion via protein-induced in-vivo cell reprogramming


Methods for treating a subject in need thereof are provided which include administering a pharmaceutical composition comprising a protein transduction reagent-modified reprogramming protein to the subject, wherein the protein transduction reagent is non-covalently bound to the reprogramming protein and wherein the protein transduction reagent comprises a cation reagent and a lipid. According to aspects, such methods provide delivery of protein-transduction reagent-modified reprogramming proteins to cancer cells, such as tumor cells, as well as diseased cells of diseased tissues and provide in vivo conversion of diseased cells into normal cells via protein-induced in situ cell reprogramming without administration of nucleic acids to the subject..
Wayne State University


Modified binding proteins inhibiting the vegf-a receptor interaction


The present invention relates to binding proteins specific for vegf-a, in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits vegf-axxx binding to vegfr-2. Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety.
Molecular Partners Ag


Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.

Active ingredient capsules


Active ingredient capsules are proposed which are obtainable by, with the input of mechanical and thermal energy, (a) dissolving and/or dispersing proteins, polysaccharides and cellulose derivatives in water, (b) adding the active ingredients to be encapsulated, (c) hardening the resulting coacervates with the addition of tannins and optionally (d) then subjecting them to a spray drying.. .
Symrise Ag


Nutrition-balancing containers and use


A four step system for weight loss in a person who is overweight or obese by introducing protein, vegetable, and starch (carbohydrate) in specific ratios to promote fat utilization and weight loss from fat composition of the person's entire body. The system utilizes portion control meal plates for weight loss in an overweight or obese person that have different protein, vegetable, and starch (carbohydrate) intake portions..

Desmoglein 2 (dsg2) binding proteins and uses therefor


The present invention provides recombinant adenoviral compositions and methods for their use in treating disorders associated with epithelial tissues.. .
University Of Washington Through It's Center For Commercialization


Inhibitors of beta integrin-g protein alpha subunit binding interactions


Provided herein are compounds that inhibit a binding interaction between a β integrin and a g protein subunit, as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog.
The Board Of Trustees Of The University Of Illinois


Method for enhancing wound healing


The invention relates to a method for enhancing wound healing in a subject in need thereof, comprising administering to the subject a composition comprising fibronectin type iii domain-containing protein 5 (fndc5) or its cleaved fragment irisin in an amount effective to enhance wound healing. .
National Sun Yat-sen University


Methods of treatment


The present disclosure provides a biochemical basis of nephrotic syndrome and provides and explanation for the observed proteinuria and other effects. As a result, the present disclosure provides method for treating and/or preventing nephrotic syndrome as well as methods of alleviating symptoms associated with nephrotic syndrome.

Agent for preventing or treating spinocerebellar ataxia


To provide a compound which enables treatment or prevention of spinocerebellar ataxia, analyses were carried out based on a screening using a spinocerebellar ataxia type 1 (sca1) fly model and on the like. As a result, the following proteins ameliorating the pathology of spinocerebellar ataxia were identified: rpa1, pnkp, xrcc3, xrcc4, ccnh, pole, polh, and peri.
National University Corporation Tokyo Medical And Dental University


Methods and products for expressing proteins in cells


The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the dna sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic rna molecules.
Factor Bioscience Inc.


Methods and products for expressing proteins in cells


The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the dna sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic rna molecules.
Factor Bioscience Inc.


Protein-polymer complex, tgase substrate-containing polymer, tgase substrate-containing monomer, producing protein-polymer complex, and improving protein function at solid-liquid interface or in vicinity of solid-liquid interface


Provided is a protein-polymer complex which is capable of detecting a target with good sensitivity. Specifically provided is a protein-polymer complex comprising a polymer having a glutamine (gln) residue or a primary amine on a side chain, wherein either a protein having a primary amine is bound to the glutamine (gln) residue, or a protein having a glutamine (gln) residue is bound to the primary amine..
Hitachi Aloka Medical, Ltd.


Il-17 receptor a antigen binding proteins


The present invention relates to il-17 receptor a (il-17ra or il-17r) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by il-17 receptor a activation by one or more il-17 ligands. The present invention relates to the identification of neutralizing determinants on il-17 receptor a (il-17ra or il-17r) and antibodies that bind thereto.
Kirin-amgen, Inc.


Method for producing polyclonal antibodies using an antigenic composition comprising protein-containing membrane vesicles


The invention relates to a method for producing polyclonal antibodies against an antigenic target protein which comprises inducing an immune response in a host by applying an immunogenic composition comprising membrane vesicles incorporating said antigenic target protein to said host and obtaining antibodies against said target protein from the host's serum. A more specific embodiment of this method comprises at least the following steps: a) synthesizing the target protein my means of an in vitro translation reaction in a reaction medium comprising a nucleic acid template coding for the target protein and a cell lysate which contains membrane vesicles; b) separating membrane vesicles comprising the synthesized target protein from the medium; c) providing the membrane vesicles comprising the synthesized target protein in a physiologically compatible medium; d) applying the membrane vesicles of step c) to a host; e) testing a serum sample of the host for a specific immune response against said target protein; and f) obtaining specific antibodies against said target protein from the serum of a host exhibiting a specific immune response against said target protein..
Fraunhofer-gesellschaft Zur FÖrderung Der Angewandten Forschung E.v.


Designed ankyrin repeat proteins binding to hepatocyte growth factor


New designed ankyrin repeat proteins with binding specificity for hgf are described, as well as nucleic acids encoding such hgf binding proteins, pharmaceutical compositions comprising such proteins and the use of such proteins in the treatment of diseases.. .
Molecular Partners Ag


Lipid co-factor essential for cell density signaling


Herein is described a cell density signaling protein and its tissue-specific lipid cofactor. Constructs, compositions and methods for isolation, purification and use of the protein and the tissue-specific lipid cofactor are described..

Bicyclic compounds


And/or a salt thereof; wherein r is —oh or —op(o)(oh)2. Also disclosed are methods of using such compounds as selective agonists for g protein-coupled receptor s1p1, and pharmaceutical compositions comprising such compounds.

Designed repeat proteins binding to serum albumin


New designed repeat proteins with binding specificity for serum albumin are described, as well as nucleic acids encoding such serum albumin binding proteins, pharmaceutical compositions comprising such proteins, the use of such proteins to modify the pharmacokinetics of therapeutic relevant polypeptides and the use of such proteins in the treatment of diseases. The repeat proteins of the invention have a substantially increased half-life in plasma compared to proteins not binding serum albumin..
Molecular Partners Ag


Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a


The present invention relates to compositions comprising haemophilus influenzae protein e and pilin a. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising protein e and pila, vaccines comprising such immunogenic compositions and therapeutic uses of the same..
Glaxosmithkline Biologicals S.a.


Galectin-3 as immunological target


Annexina2 (anxa2), a member of the annexin family of calcium-dependent, phospholipid binding proteins, is one of a panel of identified antigens recognized by the post-vaccination sera of patients who demonstrated prolonged disease-free survival following multiple vaccinations. Annexina2 is abundantly expressed in pancreatic adenocarcinomas and cell surface/membrane annexina2 increases with the progression from premalignant lesions to invasive pancreatic adenocarcinomas.
The Johns Hopkins University


Release reagent for vitamin d compounds


A reagent composition for releasing vitamin d compounds bound to vitamin d-binding protein and an in vitro method for the detection of a vitamin d compound in which the vitamin d compound is released from vitamin d-binding protein by the use of this reagent composition as well as the reagent mixture obtained in this manner. Also disclosed is the use of the reagent compositions to release vitamin d compounds as well as a kit for detecting a vitamin d compound..
Roche Diagnostics Operations, Inc.


Mass spectrometry-cleavable cross-linking agents to facilitate structural analysis of proteins and protein complexes, and using same


Where x is an n-hydroxy-succinimidyl or similar heterocyclic group. Also provided is a method of mapping protein-protein interactions of protein complexes using various mass spectrometry techniques..

Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.

Methods and kits for diagnosing, prognosing and monitoring parkinson's disease


Network-based meta-analysis of four independent microarray studies identified the hepatocyte nuclear factor (hnf4a), a transcription factor associated with gluconeogenesis and diabetes, as a central regulatory hub gene upregulated in blood of pd patients. In parallel, the polypyrimidine tract binding protein 1 (ptbp1), involved in the stabilization and mrna translation of insulin, was identified as the most downregulated gene.
Rosalind Franklin University Of Medicine And Science


Protein demethylases comprising a jmjc domain


Post-translational modification, including protein methylation, plays an important role in regulating protein function. The present invention provides a novel assay for evaluating demethylase activity and the discovery of a family of protein demethylases comprising a novel demethylase motif..
The University Of North Carolina At Chapel Hill


Methods for making proteins containing free cysteine residues


The present invention relates to novel methods of making soluble proteins having free cysteines in which a host cell is exposed to a cysteine blocking agent. The soluble proteins produced by the methods can then be modified to increase their effectiveness.
Bolder Biotechnology, Inc.


Protein scaffolds and methods of use


This disclosure describes non-naturally occurring protein scaffolds and methods of making and using the protein scaffolds. In one aspect, therefore, this disclosure describes a non-naturally occurring protein scaffold that includes a plurality of structural domains and a plurality of loop regions that include an amino acid sequence that varies from a naturally-occurring loop region by at least one amino acid deletion, substitution, or addition.
Regents Of The University Of Minnesota


Method of extracting protein


The present disclosure provides a method for extracting a soluble protein from a population of microorganisms, the method comprising contacting the population of microorganisms expressing the soluble protein with an amount of a solution comprising from about 1% (v/v) to less than 50% (v/v) carboxylic acid effective to extract the soluble protein from the population of microorganisms.. .
Elastagen Pty Ltd


Inhibitors of metallo-beta-lactamase (mbl) comprising a zinc chelating moiety


Compounds according to formula i are provided: a-l-b wherein a represents a lipophilic chelating moiety which is selective for zn2+ions; l is a covalent bond or a linker; and b is a vector which is either a moiety capable of interacting with one or more biological structures found in a bacterium (preferably in a bacterial cell wall), for example a penicillin-binding protein such as a metallo-β-lactamase or dd-transferase, or a moiety capable of enhancing transport of the compound across a bacterial cell membrane. A method of treating and/or preventing a bacterial infection in a human or non-human mammal employing such compounds are also provided.
Universitetet I Oslo


Vaccine comprising protein nmb0964 from neisseria meningitidis


The present invention relates to immunogenic compositions comprising neisserial blebs with upregulated levels of the nmb0964 antigens such that bactericidal antibodies are generated against said antigen. It has been found for the first time that this antigen's expression is zinc regulated and therefore methods are provided to upregulated expression through removal of the zinc repression mechanism of the cell or promoter, or through removal of zinc from the culture medium..
Glaxosmithkline Biologicals S.a.


Kinase modulation, and indications therefor


The present disclosure provides methods of using protein kinase inhibitors for treating diseases and conditions, including diseases and conditions associated with activity of any protein kinase selected from fms protein kinase including any mutations thereof, kit protein kinase any mutations thereof, flt-3 protein kinase any mutations thereof and combinations thereof.. .
Plexxikon Inc.


Article and controlling oral-originated obligate and facultative anaerobes and aerobic bacteria pathogens related to systemic disease


Method of treating oral subgingival biofilms having obligate anaerobes, facultative anaerobes, aerobic bacteria and other micro-organisms (collectively oral pathogens) associated with certain systemic diseases present within a subgingival biofilm having proteins and amino acids, the steps including providing a periodontal medicament delivery tray having a seal against a patient's adjacent gums containing the oral biofilms with the systemic disease, said seal formed so as to have no contact with teeth, applying to the gingival tissue (sulcus or periodontal pocket) a biofilm penetrating antimicrobial agent, removing the imbedded oral pathogens from the gingival tissue following at least one applying of the antimicrobial agent to the gingival tissue; repeatedly administering colloidal hydrogen peroxide gel to the gingival tissue following the removing; and following each administering cleaning the gingival tissue with a cleaning agent directly following the administering of the colloidal hydrogen peroxide gel for modifying the environment from anaerobic to commensal.. .

Solid phase extraction of global peptides, glycopeptides, and glycans using chemical immobilization in a pipette tip


Pipette tips comprising aldehyde-reactive or amino-reactive chemical moieties or other chemical moieties capable of conjugating to one or more reactive groups of amino acid side chains or protein modifications and methods for preparing the tips are provided. In addition, a high throughput method for identifying proteins, glycoproteins, and glycans in a plurality of samples using the pipette tips is also provided..
The Johns Hopkins University


Method for detecting proteins by means of aptamers


The present invention describes a method for an in vitro detection of a first protein in a sample, comprising the steps of: a) separating the sample by means of a native separation method; b) transferring the separated sample onto a membrane; c) contacting the membrane with an aptamer which specifically binds to the first protein; and d) detecting the first protein by detecting the aptamer bound to the first protein.. .
Technische Universität Berlin


Method for selecting a single cell expressing a heterogeneous combination of antibodies


Described are combinations of specific binding proteins, such as immunoglobulins, that are designed to be true combinations, essentially all components of the combination being functional and compatible with each other. Further provided are methods for producing a composition comprising at least two different proteinaceous molecules comprising paired variable regions, the at least two proteinaceous molecules having different binding specificities, comprising paired variable regions, at least two proteinaceous molecules having different binding specificities, comprising contacting at least three different variable regions under conditions allowing for pairing of variable regions and harvesting essentially all proteinaceous molecules having binding specificities resulting from the pairing..
Merus B.v.


Pumilio domain-based modular protein architecture for rna binding


A programmable modular protein architecture for rna binding comprises a set of modules, derived from rna-binding protein pumilio, that can be concatenated into chains of varying composition and length. When bound into a chain, each module has a preferred affinity for a specific rna base.
Massachusetts Institute Of Technology


Genetic testing for improved cattle fertility


Arrays of nucleic acid molecules, kits, methods of genotyping and marker assisted bovine breeding methods based on novel snps on genes of the bovine transforming growth factor-β (tgf-β) signaling pathway for improved bovine fertilization rate. The methods and compositions of the present invention are related to snps in the dna-binding protein inhibitor 3 (id3) gene, and in the bone morphogenetic protein 4 (bmp4) gene corresponding to position 2702 of seq id no: 2.
Wisconsin Alumni Research Foundation


Diagnostic and prognostic test for sturge-weber syndrome, klippel-trenaunay-weber syndrome, and port-wine stains (pwss)


The present invention relates to the fields of neurological and skin disorders. More specifically, the present invention provides methods and compositions for diagnosing and prognosing sturge-weber syndrome (sws), klippel-trenaunay-weber syndrome (ktws), and port wine stains (pws).
Duke University


Microbial analysis


The present invention is concerned with a method of identifying microbial strains (e.g. From a cell culture), the method comprising; i) a lipid extraction step, comprising extraction of phospholipids from the microbe, suitably with an extraction composition comprising more than 50 vol % meoh; ii) a sample preparation step, comprising preparation of a maldi sample incorporating the extracted lipids; iii) a data gathering step, comprising performing maldi-based mass spectrometry on the maldi sample, and iv) a microbe identification step, comprising analysis of the mass spectrometry data to characterise or identify the microbial strain.
Kratos Analytical Limited


Methods for the selection of binding proteins


This application provides an improved screening method for the selection of target-binding proteins having desirable biophysical properties. The method combines mrna display and yeast surface display in a way that takes advantage of the desirable attributes of both processes..
Bristol-myers Squibb Company


Synthetic single domain antibody


The invention relates to the identification of a highly stable single domain antibody scaffold (hs2d ab) and its use in generating synthetic single domain antibody library (hs2d ab-l1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics..
Centre National De La Recherche Scientifique - Cnrs


Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use


The present disclosure provides chimeric proteins having an n-terminus coupled to a c-terminus, wherein the n-terminus comprises an n-terminal portion of fibroblast growth factor (fgf) 2 and the c-terminus comprises a portion of an fgf1 protein. Such fgf2/fgf1 chimeras can further include a fibroblast growth factor receptor (fgfr) 1c-binding protein, a β-klotho-binding protein, or both.
Salk Institute For Biological Studies


Method for improving blood persistence of protein


Provided herein is a means for increasing protein retention in blood. The protein retention in blood is increased by forming a conjugate of a protein and chondroitin produced by a microorganism having chondroitin-producing capability and/or chondroitin synthesized with a chondroitin synthase..
Seikagaku Corporation


Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.

Chimeric factor h binding proteins (fhbp) and methods of use


Chimeric fhbps that can elicit antibodies that are bactericidal for different fhbp variant strains of n. Meningitidis, and methods of use, are provided..
Children's Hospital & Research Center Oakland


Compositions and the use of fibrinogen binding motif presence in efb and coa for vaccine against staphylococcus aureus and drug delivery


The present disclosure provides methods and composition including vaccines, monoclonal antibodies, polyclonal antibodies, chimeric molecule of an extracellular fibrinogen binding protein (efb) and targeted agent delivery pharmaceutical composition comprising at least a portion of a modified n-terminus region, at least a portion of a modified c-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in inhibiting the fibrinogen binding, c3 binding, or both or administering to a subject a pharmacologically effective amount of a vaccine in a pharmaceutically acceptable excipient, comprising a modified extracellular fibrinogen binding protein comprising at least a portion of a modified n-terminus region, at least a portion of a modified c-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in not shielding the staphylococcus bacterium from recognition by a phagocytic receptor.. .
University Medical Center Utrecht, The Netherlands


Immuno-oncolytic therapies


The present invention relates to oncolytic vaccinia viruses which have been modified to promote anti-tumor immunity and/or reduce host immunity and/or antibody response against the virus. It is based, at least in part, on the discovery that oncolytic vaccinia virus (i) bearing a genome deletion of a gene that reduces t cell immunity (interleukin-18 binding protein); (ii) treated with a sialidase enzyme which is believed to reduce tlr2 activation and therefore the antibody response; (iii) carrying a gene that enhances cytotoxic t lymphocyte induction (e.g., trif) and/or (iv) reduces tumor myeloid-derived suppressor cells by reducing prostaglandin e2 reduces tumor growth.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education


Molecular imaging methods for diagnosis and evaluation of ocular and systemic diseases


This invention relates generally to minimally-invasive, in vivo methods of detecting one or more ligands on an intraluminal surface of a blood vessel using microparticles coated with one or more ligand binding partners. More particularly, in certain embodiments, the invention relates to minimally-invasive, in vivo methods of detecting endothelial and leukocyte antigens that are predictive of diabetic retinopathy (dr) and/or other conditions using protein-conjugated microparticles detectable by a non-invasive detection system, for example, a scanning laser ophthalmoscope.
Massachusetts Eye And Ear Infirmary


Activated formylglycine-generating enzymes and methods of producing and using the same


The present disclosure provides activated formylglycine-generating enzymes (fge), methods of producing activated fge, and their use in methods of producing a protein comprising a formylglycine (fgly) residue. The methods of producing activated fge, as well as methods of use of activated fge in producing fgly-containing proteins, include both cell-based and cell-free methods.
R.p. Scherer Technologies, Llc


Polynucleotide encoding acyl-coa synthetase homolog and use thereof


The present invention relates to an acyl-coa synthetase homolog protein from microorganisms of the genus mortierella, a polynucleotide encoding the protein, and so on. The invention provides polynucleotides comprising an acyl-coa synthetase homolog protein gene from, e.g., mortierella alpina, expression vectors comprising these polynucleotides and transformants thereof, a method for producing lipids or fatty acids using the transformants, food products containing the lipids or fatty acids produced by the method, etc..
Suntory Holdings Limited


Polynucleotide encoding acyl-coa synthetase homolog and use thereof


The present invention relates to an acyl-coa synthetase homolog protein from microorganisms of the genus mortierella, a polynucleotide encoding the protein, and so on. The invention provides polynucleotides comprising an acyl-coa synthetase homolog protein gene from, e.g., mortierella alpina, expression vectors comprising these polynucleotides and transformants thereof, a method for producing lipids or fatty acids using the transformants, food products containing the lipids or fatty acids produced by the method, etc..
Suntory Holdings Limited


Tm4sf1 binding proteins and methods of using same


This present invention relates to compounds (e.g., tm4sf1 binding proteins, e.g., anti-tm4sf1 antibodies) that specifically bind to a polypeptide at an epitope including an amino acid sequence of seq id no: 1. In particular, the compounds of the invention are capable of being internalized into a tm4sf1-expressing cell (e.g., a tumor cell or an angiogenic vasculature endothelial cell) following binding to the epitope of including the amino acid sequence of seq id no: 1.
Beth Israel Deaconess Medical Center, Inc.


Mice that produce antigen-binding proteins with ph-dependent binding characteristics


Genetically modified non-human animals are provided that comprise an immunoglobulin heavy chain locus comprising an unrearranged human heavy chain variable region nucleotide sequence comprising an addition of at least one histidine codon or a substitution of at least one endogenous non-histidine codon with a histidine codon. Compositions and methods for making the genetically modified non-human animals as described herein are provided.
Regeneron Pharmaceuticals, Inc.


Photoreactive synthetic regulator of protein function and methods of use thereof


The present disclosure provides a photoreactive synthetic regulator of protein function. The present disclosure further provides a light-regulated polypeptide that includes a subject synthetic regulator.
The Regents Of The University Of California


Inhibitors of valosin-containing protein and methods of use


A method of inhibiting aberrant valosin-containing protein (vcp) accumulation in the mitochondria of a nerve cell includes administering to the nerve cell a therapeutic agent that inhibits the binding or complexing of vcp with a polyglutamine protein.. .
Case Western Reserve University


Stable solid units and methods of making the same


The invention provides stable solid compositions of a therapeutic agent, such as a protein, (e.g., an antibody, a peptide, or a dvd-ig protein), and a stabilizer, such as a sugar, and methods of preparing and using the same. The invention further provides a generalized therapeutic agent delivery form wherein the active components are in a lyophilized, stable configuration, and, in some embodiments, prepared independently from the primary container..
Abbvie Inc.




G Protein topics:
  • Antibodies
  • Nucleic Acid
  • G Proteins
  • Nucleic Acids
  • Amino Acid
  • Polypeptide
  • Protein A Affinity Chromatography
  • Chromatography
  • Chromatograph
  • Liver Metastasis
  • Membrane Protein
  • Colorectal Carcinoma
  • Rectal Carcinoma
  • Prophylactic
  • Glycoprotein


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to G Protein for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for G Protein with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.9676

    4631

    1 - 1 - 102